Pyrrole-2-Aldehyde

Antiviral Nucleotide Analogue Synthesis: Defining the Point of ICH Q11 Regulatory Commitment

The synthesis of the antiviral prodrug remdesivir (GS‑5734) hinges on a critical pyrrolo[2,1‑f][1,2,4]triazin‑4‑amine heterocycle, for which pyrrole‑2‑aldehyde is formally designated as the regulatory starting material in filings reviewed under ICH Q11. Commercial multi‑kilogram campaigns executed in Hastelloy C‑22 jacketed reactors (2000 L working volume, 3‑bar MAWP) with nitrogen inertisation charge pyrrole‑2‑aldehyde (assay ≥99.5 %, any single impurity <0.15 %) at a controlled molar ratio of 1.00 : 1.05 relative to cyanamide in anhydrous N,N‑dimethylformamide (water <0.01 % Karl Fischer) at −5 °C to 0 °C. This stoichiometric relationship prevents the persistence of unreacted aldehyde, which otherwise forms potentially genotoxic Schiff‑base adducts with the downstream (S)‑2‑ethyl‑1‑butanol amine component, triggering ICH M7 impurity alerts in the dried drug substance. Phosphoryl chloride (1.8 eq.) is metered over 90 min while maintaining jacket temperature at −8 °C; the resulting N‑cyanoimine intermediate cyclises upon gradual heating to 85 °C over 6 h, monitored by in‑line Raman spectroscopy (pyrrolotriazine ring breathing mode at 1270 cm⁻¹). Direct chlorination with additional POCl₃ under reflux (107 °C) and final nucleophilic amination at 40 °C in tetrahydrofuran are run telescoped to limit open handling of the chlorotriazine intermediate. Isolated hydrochloride salt is dried under vacuum (≤10 mbar, 45 °C) to meet residual solvent specifications in accordance with ICH Q3C Option 2: DMF <880 ppm, tetrahydrofuran <720 ppm, and toluene <890 ppm. Conformance to ICH Q3D elemental impurity class limits is verified by ICP‑MS on every batch before coupling to the phosphoramidate side chain, with palladium and nickel individually controlled below 2.0 µg/g. The final drug substance is sterile‑filtered through 0.22 µm PVDF membranes and lyophilised into single‑dose vials containing 100 mg remdesivir, meeting the specifications of the FDA‑approved prescribing information for Veklury® and USP <797> compounding requirements for parenteral administration. Process deviation reports from commercial launch campaigns indicate that the primary batch failure mode is a ±3 °C excursion from the −2 °C POCl₃ charge setpoint, which produces a dichlorinated dimer impurity that exceeds the 0.10 % rejection threshold and mandates batch re‑processing.

Accessing asymmetrical A₃B porphyrin architectures for clinical photosensitiser production relies on the acid‑catalysed condensation of pyrrole with aldehydes, and pyrrole‑2‑aldehyde supplies the aldehyde‑bearing pyrrole unit that differentiates the macrocycle from symmetrical tetraphenylporphyrin variants. Under rigorous anaerobic conditions maintained by argon sparging and a glovebox O₂ sensor reading <10 ppm, a Lindsey cyclisation charges pyrrole‑2‑aldehyde and 4‑methoxybenzaldehyde at a molar ratio of 1 : 3.2 : 4 (pyrrole‑2‑aldehyde : aryl aldehyde : freshly distilled pyrrole) in dichloromethane (0.18 M total pyrrole concentration), with BF₃·OEt₂ (0.33 eq. relative to total aldehyde) added at 22 °C ± 1 °C. After 1.5 h condensation, the porphyrinogen mixture is oxidised with 2,3‑dichloro‑5,6‑dicyano‑1,4‑benzoquinone (1.1 eq.) for 45 min, and 5‑(pyrrol‑2‑yl)‑10,15,20‑tris(4‑methoxyphenyl)porphyrin is purified by flash chromatography (silica 60 Å, 15–40 µm particle size, elution from hexane/ethyl acetate 4:1 to 3:2) to a minimum 98.5 % HPLC purity. The purified free base is metalated with Zn(OAc)₂·2H₂O (10 eq.) in dimethylformamide at 80 °C for 3 h and crystallised from methanol/water. For a liposomal injectable photosensitiser, the zinc complex is incorporated into a lipid film of DPPC:DPPG 9:1 (w/w) at a drug loading of 1.5 mg/mL, hydrated in phosphate‑buffered saline (pH 7.4), and extruded through stacked 200 nm polycarbonate track‑etch membranes in a temperature‑controlled barrel extruder at 50 °C. The finished liposomal dispersion is terminally sterilised by 0.22 µm filtration and tested for bacterial endotoxin (USP <85>, limit <1.0 EU/mg) and sterility per ISO 11737‑2. The active substance monograph aligns with the European Pharmacopoeia standard for temoporfin‑type photosensitisers ( 01/2024:2647 ), and the drug product is approved for interstitial photodynamic therapy of recurrent head and neck squamous cell carcinoma, with photoactivation at 652 nm delivered through a fibre‑optic diffuser. Scale‑up experience in a multiproduct cGMP facility reveals that the photobleaching quantum yield coefficient of variation stays below 8 % only when the Lindsey condensation vessel is shielded with light‑tight sleeves filtering wavelengths below 650 nm; stray UV exposure during scale‑up precipitated porphyrinogen scrambling that increased the content of the unwanted A₂B₂ regioisomer above the 1.0 % clinical specification.

FEMA 2496 Status: Direct Flavourant Application in Thermally Processed Bakery Products and Coffee Extenders

Pyrrole‑2‑aldehyde (CAS 1003‑29‑8) is listed in the FEMA GRAS inventory as No. 2496 and evaluated by the Joint FAO/WHO Expert Committee on Food Additives (JECFA 2133) with an acceptable daily intake of “not specified,” enabling its direct use as a character‑impact odourant in compounded flavourings without in‑situ chemical transformation. Commercial flavour houses prepare a 1.0 % w/w dilution of neat pyrrole‑2‑aldehyde (GC purity ≥99.0 %, moisture <0.2 % by Karl Fischer) in propylene glycol or triacetin under low‑shear mixing at 20–25 °C to prevent aldehyde‑sensitive matrix reactions that would occur if the neat aldehyde were added directly to a dry blend containing free amine‑bearing ingredients. In a standard cracker‑type baked dough formulation, the 1 % stock solution is metered through a peristaltic weight‑loss micro‑doser at 0.05–0.2 g per 100 kg dough batch, delivering a finished‑product pyrrole‑2‑aldehyde concentration of 0.5–2.0 ppm; for reconstituted soluble coffee powders, the target concentration is increased to 5 ppm to amplify the dark‑roast pyrazine‑pyrrole synergy characteristic of Robusta blends. The dosage range falls entirely within the maximum permitted levels of the Union list of flavourings and source materials in Regulation (EC) 1334/2008 Annex I. Incoming‑lot quality control relies on GC‑FID quantitation against a certified reference standard (Sigma‑Aldrich CRM 46756) and orthonasal odour threshold verification (detection in water at 0.1 ppm). Batches exhibiting an oxidised 1H‑pyrrole‑2‑carboxylic acid peak exceeding 0.5 area% are rejected because the acid survives the 180–220 °C baking profile and imparts a sour‑musty off‑note in the finished biscuit. Down‑stream factory incorporation deploys a ribbon blender pre‑mix charged with the micro‑doser; the only identified critical process parameter is a minimum 15‑minute mixing time required to achieve a coefficient of variation <5 % in pyrrole‑2‑aldehyde concentration before the fat encapsulation phase. End‑use consumer goods include shelf‑stable crackers with 12‑month ambient shelf life, ready‑to‑drink canned coffee beverages aseptically filled at 95 °C, and microwave popcorn seasoning salts that must remain free‑flowing at 40 % relative humidity.

When Hydrochloric Acid Pickling Exceeds 60°C, the Corrosion Inhibitor Requires a Pyrrole Schiff‑Base Boost

Continuous steel pickling tunnels running 15–20 % w/w hydrochloric acid at strip speeds above 120 m/min demand inhibitor packages that maintain a corrosion rate below 5.0 mm/y on exposed substrate, and the Schiff base condensed from pyrrole‑2‑aldehyde and diethylenetriamine (PSB‑DETA, 1 : 1.05 molar ratio in refluxing ethanol, 4 h) provides a mixed‑type inhibition mechanism confirmed by Tafel extrapolation per ASTM G59‑97 at a scan rate of 0.5 mV/s. Weight‑loss coupon evaluations on AISI 1045 panels in 15 % HCl at 25 °C under 6‑hour static immersion (ASTM G31‑72) show that PSB‑DETA dosed at 400 mg/L reduces the general corrosion rate from 12.4 mm/y to below 0.9 mm/y, reflecting an inhibition efficiency exceeding 92 %. When the bath temperature exceeds 60 °C, however, the inhibition efficiency collapses to 55–65 % irrespective of concentration, owing to thermal desorption of the protonated imine film as traced by the disappearance of the N 1s component at 398.5 eV in X‑ray photoelectron spectra of the tested coupons. Continuous coil pickling lines where rinse‑section heat carryover pushes the acid temperature to 65–70 °C reformulate the additive with 50 mg/L potassium iodide and 100 mg/L propargyl alcohol as synergistic agents, restoring a stable mixed inhibitor film and shifting the corrosion current density in polarisation scans to below 25 μA/cm². A three‑stage counter‑flow pickling tunnel at a cold‑rolling mill enforces that the recirculated acid maintain a turbidity below 15 NTU (ISO 7027‑1) because colloidal ferric hydroxide particles above that threshold scavenge inhibitor molecules and leave bare steel streaks; side‑stream circulation through 5 μm polypropylene bag filters with a 10 % bleed ratio resolves the issue. The formulated additive is supplied as a 30 % active solution in isopropanol, packaged in nitrogen‑blanketed HDPE totes, and monitored for residual free aldehyde by DNPH derivatisation HPLC (specification <0.3 % as pyrrole‑2‑aldehyde), because any free aldehyde undergoes slow aldol polymerisation that forms insoluble particulates blocking the injection nozzle filters. Registration documentation for the pickle‑liquor additive includes a REACH compliance dossier (Reg. 1907/2006, Annex VII) and an acute aquatic toxicity profile determined per OECD 203 (96‑h LC₅₀, Danio rerio > 100 mg/L).

Porphyrin dyes employed in dye‑sensitized solar cells demand high molar extinction coefficients and energy‑level alignment with the conduction band edge of TiO₂, and the pyrrole‑2‑aldehyde‑derived sensitizer 5‑(pyrrol‑2‑yl)‑10,20‑diphenylporphyrinatozinc(II), equipped with a cyanoacrylic acid anchoring group, achieves panchromatic photon harvesting when co‑sensitised with an organic push‑pull chromophore such as MK‑2. The backbone porphyrin is built via an Adler‑Longo condensation at 120 °C in neat propionic acid (0.15 M total aldehyde), dosing pyrrole‑2‑aldehyde at 15 mol% of the total aldehyde charge alongside benzaldehyde and pyrrole to introduce the pyrrole side‑arm that is subsequently formylated and condensed with cyanoacetic acid in a Knoevenagel reaction (piperidine/acetonitrile, 82 °C, 6 h). The sensitizer is dissolved in anhydrous ethanol (0.2 mM) and loaded onto 12 µm transparent TiO₂ photoanodes (screen‑printed from 18 nm anatase paste, active area 0.25 cm²) by immersion for 4 h at 40 °C in a sealed double‑jacket vessel; the headspace is continuously purged with argon maintaining a dew point below −60 °C because ethanol uptake of ambient moisture above 100 ppm H₂O triggers hydrolytic cleavage of the ester‑type anchor group, causing a 40 % drop in photocurrent within 48 h of light‑soaking. Photovoltaic performance tested under AM 1.5G irradiance (100 mW/cm²) with an I⁻/I₃⁻ redox couple in acetonitrile/valeronitrile (85:15) and a platinised FTO counter electrode yields an open‑circuit voltage of ≥710 mV and a short‑circuit current density of ≥10.5 mA/cm², recorded in compliance with IEC 60904‑3 spectral mismatch correction. Roll‑to‑roll manufacture on flexible ITO‑PEN substrates requires encapsulation with a UV‑curable ethylene vinyl acetate resin cured at 150 °C for 15 min, and the entire foil stack must pass EU RoHS 2011/65/EU screening by ED‑XRF (Pb <1000 ppm, Cd <100 ppm, Cr⁶⁺ <1000 ppm). The final product class is an indoor low‑light flexible DSSC strip for powering autonomous IoT sensor nodes, fabricated in an ISO 7 cleanroom to avoid particle‑induced micro‑shorts, and the bill of materials explicitly prohibits halogenated solvents beyond the synthetic step so that the finished component meets IEC 61249‑2‑21 halogen‑free requirements for electronics.